Fundamental analysis · SEC EDGAR · as of 24/04/2026

Fundamental analysis of Medtronic Plc

MDT · NYSE · Electromedical & Electrotherapeutic Apparatus

Fundamental quality

REASONABLE

67

out of 100

Breakdown by area

I.GrowthEPS: 9.8% · Revenue: 5.2%
53
II.ProfitabilityNet margin: 13.2% · ROE: 9.7%
73
III.Financial healthNet debt/EBITDA: 2.33x · FCF: 14.9%
74

Source: SEC EDGAR · as of 24/04/2026

Reading the numbers

On average over recent years, earnings per share grew 9.8% a year and revenue advanced 5.2% a year.

On profitability, Medtronic Plc shows a net margin of 13.2%, a gross margin of 57.5%, an ROE of 9.7%.

Its financial health shows net debt of 2.33 times its EBITDA and a free cash flow margin of 14.9%.

Adding up growth, profitability and financial strength, the traffic light gives MDT a fundamental quality of 67 out of 100. To also know whether it's cheap or expensive, the price is missing: enter it in the tool and you'll get the valuation verdict (P/E against its sector).

The thresholds are general and the system doesn't judge qualitative factors. See the full methodology and use this analysis as a first filter, never as a final decision.

Is Medtronic Plc cheap or expensive?

That depends on the current price. Look it up, enter it in the tool and get the full valuation verdict (P/E against its sector).

Compute the valuation →
Advertising

Where to buy Medtronic Plc?

Brokers you can use to invest in U.S. and European stocks.

Compare the brokers →